Shares of Biocon Ltd on Tuesday shed early gains and settled 1 per cent lower after gaining nearly 5 per cent in early trade.
The stock closed 1.01 per cent lower at Rs 283.05 on the BSE. During early market hours, the stock went up 4.80 per cent to Rs 299.70.
On the NSE, the scrip closed 0.58 per cent lower at Rs 284.15. It gained as much as 4.61 per cent to touch a high of Rs 299 in early trade.
Over 1 crore shares of Bicon were traded on the NSE during the day, while the BSE witnessed an exchange of 7.88 lakh shares.
Biocon and drug firm Mylan NV on Monday announced the launch of biosimilar Ogivri, used for treatment of certain breast and gastric cancers, in the US market.
"We aspire to serve 5 million patients through our biosimilars portfolio and cross a revenue milestone of USD 1 billion by FY22," Biocon Biologics CEO Christiane Hamacher said.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
